YU84403A - Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina - Google Patents

Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina

Info

Publication number
YU84403A
YU84403A YU84403A YUP84403A YU84403A YU 84403 A YU84403 A YU 84403A YU 84403 A YU84403 A YU 84403A YU P84403 A YUP84403 A YU P84403A YU 84403 A YU84403 A YU 84403A
Authority
YU
Yugoslavia
Prior art keywords
intermediates
aminochinoline
derivates
compounds useful
useful
Prior art date
Application number
YU84403A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU84403A publication Critical patent/YU84403A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formula Gde je A, CN, COONH2 ili CONHCOOR, gde je R metil ili po potrebi supstituisan benzil, a koja su korisna kao intermedijeri za inhibitore holesteril estar transfer proteina (CTP) i postupke njihovog dobijanja.[This invention relates compounds of formulae Wherein A is CN,CONH2 OR CONHCOOR, R being methyl or optionally substituted benzyl, useful as intermediates for cholesteryl ester transfer protein (CETP) inhibitors and methods for the preparation thereof.
YU84403A 2001-04-30 2002-04-08 Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina YU84403A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
YU84403A true YU84403A (sh) 2006-08-17

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
YU84403A YU84403A (sh) 2001-04-30 2002-04-08 Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina
YU84303A YU84303A (sh) 2001-04-30 2002-04-08 Postupak dobijanja cetp inhibitora

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU84303A YU84303A (sh) 2001-04-30 2002-04-08 Postupak dobijanja cetp inhibitora

Country Status (25)

Country Link
US (3) US6689897B2 (sh)
EP (2) EP1383734B1 (sh)
JP (2) JP3924251B2 (sh)
KR (2) KR100639745B1 (sh)
CN (3) CN1267411C (sh)
AR (3) AR035963A1 (sh)
AT (2) ATE316957T1 (sh)
AU (1) AU2002253448B2 (sh)
BR (2) BR0209291A (sh)
CA (2) CA2445623A1 (sh)
CZ (2) CZ20032900A3 (sh)
DE (2) DE60210265T2 (sh)
DK (2) DK1425270T3 (sh)
ES (2) ES2259080T3 (sh)
HK (1) HK1062294A1 (sh)
HU (2) HU225777B1 (sh)
IL (2) IL157544A0 (sh)
MX (2) MXPA03009936A (sh)
PL (2) PL366584A1 (sh)
PT (1) PT1425270E (sh)
RU (2) RU2259355C2 (sh)
TW (1) TWI250974B (sh)
WO (2) WO2002088085A2 (sh)
YU (2) YU84403A (sh)
ZA (2) ZA200306600B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60331873D1 (de) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
JP4644658B2 (ja) * 2003-02-18 2011-03-02 高砂香料工業株式会社 光学活性テトラヒドロキノリン類の製造方法
WO2004083166A1 (ja) * 2003-03-17 2004-09-30 Kaneka Corporation （ｒ）－３－［４－（トリフルオロメチル）フェニルアミノ］－ペンタン酸アミド誘導体の製造法
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
EP1670446A2 (en) 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
CN101018770A (zh) * 2004-04-07 2007-08-15 千禧药品公司 炎性疾病治疗用pgd2受体拮抗剂
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
WO2012141487A2 (en) 2011-04-12 2012-10-18 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for cetp inhibitor
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
HUE033790T2 (en) 2013-01-31 2017-12-28 Chong Kun Dang Pharmaceutical Corp CETP inhibitor biaryl or heterocyclic biaryl substituted cyclohexene derivatives
CN105706289A (zh) * 2013-11-11 2016-06-22 隆萨有限公司 利用路易斯酸制备第13族元素的氰基化合物的方法
WO2016024858A1 (en) * 2014-08-12 2016-02-18 Dezima Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336691C (en) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
DE60209004D1 (de) 2006-04-13
BR0209291A (pt) 2004-07-13
US6689897B2 (en) 2004-02-10
KR100591998B1 (ko) 2006-06-22
CN1529696A (zh) 2004-09-15
WO2002088069A3 (en) 2003-02-20
EP1383734B1 (en) 2006-02-01
HK1062294A1 (en) 2004-10-29
CA2445693A1 (en) 2002-11-07
ES2259080T3 (es) 2006-09-16
HUP0304041A2 (hu) 2004-04-28
ZA200306600B (en) 2004-08-25
DE60210265D1 (de) 2006-05-18
AR035963A1 (es) 2004-07-28
KR20040015200A (ko) 2004-02-18
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
DE60210265T2 (de) 2006-10-12
DE60209004T2 (de) 2006-09-28
PL366700A1 (en) 2005-02-07
ES2256461T3 (es) 2006-07-16
CA2445623A1 (en) 2002-11-07
CN1297541C (zh) 2007-01-31
EP1425270B1 (en) 2006-03-29
RU2265010C2 (ru) 2005-11-27
CN1267411C (zh) 2006-08-02
AU2002253448B2 (en) 2007-07-05
IL157546A0 (en) 2004-03-28
HUP0304039A3 (en) 2005-10-28
HU225777B1 (en) 2007-08-28
CN1680292A (zh) 2005-10-12
CN100357265C (zh) 2007-12-26
AR044706A2 (es) 2005-09-21
CZ20032900A3 (cs) 2004-06-16
EP1425270A2 (en) 2004-06-09
RU2003131871A (ru) 2005-04-10
PL366584A1 (en) 2005-02-07
JP3924251B2 (ja) 2007-06-06
JP3924250B2 (ja) 2007-06-06
MXPA03009936A (es) 2004-01-29
KR100639745B1 (ko) 2006-10-30
JP2004527556A (ja) 2004-09-09
WO2002088085A3 (en) 2004-03-25
JP2004531541A (ja) 2004-10-14
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
MXPA03009935A (es) 2004-01-29
ZA200306599B (en) 2004-10-22
WO2002088085A2 (en) 2002-11-07
CZ20032898A3 (cs) 2004-07-14
PT1425270E (pt) 2006-07-31
EP1383734A2 (en) 2004-01-28
YU84303A (sh) 2006-05-25
US20030216576A1 (en) 2003-11-20
ATE316957T1 (de) 2006-02-15
DK1383734T3 (da) 2006-05-15
US6600045B2 (en) 2003-07-29
IL157544A0 (en) 2004-03-28
RU2003131870A (ru) 2005-01-27
WO2002088069A9 (en) 2003-12-04
CN1505609A (zh) 2004-06-16
ATE321755T1 (de) 2006-04-15
US20020177716A1 (en) 2002-11-28
HUP0304041A3 (en) 2005-08-29
TWI250974B (en) 2006-03-11
US6706881B2 (en) 2004-03-16
HUP0304039A2 (hu) 2004-03-29
DK1425270T3 (da) 2006-07-03
US20030073843A1 (en) 2003-04-17
WO2002088069A2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
YU84403A (sh) Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina
PL372799A1 (en) New compounds
AU2002316137A1 (en) Method of determining protein interaction inhibitors
MXPA03007043A (es) Nueva sal de succinato de o-desmetil-venlafaxina.
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
EE200200277A (et) 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
ATE338550T1 (de) Mikronisierter zolpidem hemitartrat
BRPI0408466B8 (pt) composição farmacêutica e uso de inibidor de proteína de transferência de colesteril éster e crospovidona
IL155041A0 (en) Process for the preparation of n-(substituted phenyl)-3-alkyl-, aryl-and heteroarylsulfonyl-2-hydroxy-2-alkyl-and haloalkylpropanamide compounds
AU2002238103A1 (en) Use of beta-lactamase inhibitors as neuroprotectants
WO2004046293A3 (en) Amphoteric fluorescent whitening agents
MXPA01006469A (es) Combinaciones de inhibidores de proteina de transferencia de ester colesterilico y derivados de acido fibrico para indicaciones cardiovasculares.
AU2003251681A1 (en) Ghrelin binding nucleic acids
EP1191015A4 (en) AMINO STYRENE R THEN DERIVATIVES, INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND METHOD FOR THE PRODUCTION OF BOTH
AU1651001A (en) Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof
HK1049336A1 (en) Synthetic routes for the preparation of rhinovirusprotease inhibitors and key intermediates.
AU2001270131A1 (en) Screen for identifying inhibitors of glycosylphosphatidylnositol anchoring
AU2001277728A1 (en) Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
EP1467978A4 (en) "COMPOUNDS THAT CONTAIN VACCINATES DRUG LIPASE, THEIR SYNTHESIS AND USE"
AU2001280234A1 (en) Myricetin as an inhibitor of serotonin n-acetyltransferase
AU2002346812A1 (en) Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors
AU2002302699A1 (en) Method for detecting activator or inhibitor compounds of receptors of the family of the insulin receptor using an isolated chimeric receptor
PL1622926T3 (pl) Nowy sposób i produkty pośrednie wytwarzania związków 19-norsteroidów fluorowcowanych w pozycji 17